Impact of biotechnology on the diagnostics of thrombotic disorders.
The use of monoclonal antibodies, genetic engineering, and recombinant molecules have greatly affected the diagnostics and therapeutics of thrombotic disorders. Future diagnostics and therapeutics will use chimeric or bifunctional antibodies, DNA probes, and perhaps liposomes in order to improve sensitivity and therapeutic efficacy. These highly sensitive and specific immunochemical tools also allow us to quantitate the activities of the various steps of the hemostatic mechanism in vivo at subnamolar levels.
Carroll
J J
JJ
Ortho Diagnostic Systems, Inc., Raritan, New Jersey.
D000911:Antibodies, Monoclonal; D001709:Biotechnology; D001780:Blood Coagulation Tests; D006023:Glycoproteins / Q000032:analysis / Q000172:deficiency; D006801:Humans; D011486:Protein C / Q000032:analysis; D020151:Protein C Deficiency; D017293:Protein S; D011994:Recombinant Proteins; D013927:Thrombosis / Q000175:diagnosis*
D000911:Antibodies, Monoclonal; D006023:Glycoproteins; D011486:Protein C; D017293:Protein S; D011994:Recombinant Proteins